Mitsubishi's LACRIS probiotic hits US market

Mitsubishi's LACRIS probiotic hits US market

SupplySide West attendees will learn how stability and longevity set Mitsubishi’s flagship probiotic apart from the crowd.

On Oct. 8 American markets will be introduced to a product that has benefited consumers in Japan for nearly 50 years. LACRIS probiotic from Mitsubishi-Kagaku Foods Corp. of Japan, was first isolated from green malt in 1949, and by 1966 was featured widely in Japan’s sophisticated health food and supplement market. A resounding success in its native country for 48 years, now producers of health foods, supplements and all health-concerned enterprises in the U.S. will come to know why.

Marketers and manufacturers know that the probiotic field is exploding, and the reasons couldn’t be clearer.

Bolstering the body’s own formidable defenses is an abiding health goal for a world of better-informed, health-conscious consumers, who have become increasingly wary of introducing synthetics and pharmaceuticals to their system. The media streams with news and information about probiotics and their positive effect on regularity and digestion, as well as a constellation of benefits that include resistance to airborne allergens and food toxins. Consumers are more familiar than ever with their many advantages and are eager for dependable, desirable natural food products that can provide them.

The  introduction of  LACRIS (Bacillus coagulans SANK70258) from Mitsubishi-Kagaku Foods Corp. offers the opportunity to make clear that not everything called probiotic works the same way, comes from the same natural source, or can promise benefits that are supported by clinical study.

The Lacris distinction
The living presence of a given probiotic in the lower intestine is integral to its effectiveness. In the battle against the deteriorating effects of airborne disease, toxins, and pollutants, the body is doing its part at every moment to amass its defenses. Its ability to maintain health pivots on the balance tipping in favor of those defenses. Antibiotics are a miracle of last century’s pharmacological technology, but they achieve that balance by subtracting harmful bacterial presence. In doing this, however, they attack all bacterial presence, including those organisms that stimulate the immune system to action. The result, an internal environment that is safer in the near term but not stronger.

Bifidobacteria, which comprise the largest share of popular probiotic ingredients, can help. But their physical properties—they are anaerobic and incapable of sporogenesis—make it difficult for them to maintain an effective presence in the lower intestine without ingestion of large amounts.

Administration of just 20 mg of LACRIS introduces 100 million active bacilli to the intestine. Daily doses of 20 to 40 mg have been clinically proven to restructure the intestine’s floral environment, resulting in improvements to the form and content of waste, as well as its regularity and the condition of the bowel. LACRIS is remarkably resistant to acid. It has been demonstrated to remain intact in the intestine without being affected by gastric acid, and in fact can stand up to a pH environment as high as 2.0. Further, it has a survival rate of over 70 percent when preserved at 37 degrees Centigrade for three years, a tribute to its stability and consequent shelf life. LACRIS also exhibits astonishing heat resistance. Most lactic acid bacteria die at 70 degrees C. LACRIS can be sustained for up to 30 minutes at temperatures as high as 85 C with almost no diminishment in number. That means that it can be easily processed, for example, into “gummy” chewables, a form that now enjoys huge popularity in American supplements and that, along with biscuits and other extremely popular foods, has been marketed in Japan for years.

These are the key features that set LACRIS apart: LACRIS is exceptionally stable, standing up to heat and high acidity; it is aerobic, which allows it to thrive in the intestinal environment, and thus vitalized, go to work producing spores in large number, so that even with doses limited to as little as 20 to 40 milligrams it continues to proliferate in both sample volume and beneficial effect. Immune system balance is achieved not by eliminating a greater number of harmful antigens, but by amplifying the number of living beneficial bacteria, and thus crowding them out—truly protection in numbers.

For producers, the combination of low dosage, high resistance to heat and acidity, and high stability means that LACRIS surpasses other probiotics in versatility and efficiency of use. The point of good health is not slowing down, and from hot cereals and beverages to everyday gummy supplements, consumers want the benefits of probiotic health to become a feature of their life without having to adhere to a special regimen or diet. LACRIS affords this with a level of effectiveness that is backed by clinical proof.

Mitsubishi-Kagaku Foods Corp. is welcoming LACRIS to the U.S. in a big way, with a major introduction, new marketing and graphics, and an open invitation to producers and researchers alike to learn more about our derivation process, our clinical methodologies and study conclusions. Please visit us at Supply Side West this October (Booth 18101), and see why Mitsubishi LACRIS is destined to change the way probiotics are viewed and used by consumers and professionals going forward.




Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.